Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanchang
Clinical trial register · China

Clinical Trials in Nanchang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19282 matching records held by the registry are in this view. Synced 14 Nov 2026, 03:17 UTC
19282
Studies in scope
all four open statuses
11840
Recruiting now
open to new participants
2032
Lead sponsors
across recruiting studies
Top sites
Beijing 5606 Shanghai 3892 Guangzhou 3359 Hangzhou 1833 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Nanchang University37 AbbVie15 The First Affiliated Hospital of Nanchang University13 Pfizer12 Sun Yat-sen University12 Sanofi11 Jiangxi Provincial Cancer Hospital11 Novartis Pharmaceuticals10 Merck Sharp & Dohme LLC10 Hoffmann-La Roche10 AstraZeneca8 Eli Lilly and Company8 Janssen Research & Development, LLC6 Second Affiliated Hospital, Zhejiang University, School of Medicine6 Daiichi Sankyo5 GlaxoSmithKline5 Boehringer Ingelheim5 Changchun GeneScience Pharmaceutical Co., Ltd.4 BeOne Medicines4 First Affiliated Hospital of Zhejiang University4 Bristol-Myers Squibb4 Institute of Hematology & Blood Diseases Hospital, China4 Nanchang University Affiliated Rehabilitation Hospital3 Bin Cao3 Shanghai Zhongshan Hospital3 Show all 201
Site location
Beijing5606 Shanghai3892 Guangzhou3359 Hangzhou1833 Wuhan1342 Chengdu1310 Nanjing1216 Changsha1159 Chongqing1085 Fuzhou1041 Tianjin940 Zhengzhou926 Hefei909 Jinan794 Changchun642 Shenzhen585 Harbin549 Nanchang449 Nanning443 Xi'an443 Suzhou433 Shenyang406 Xiamen391 Shijiazhuang351 Lanzhou273 Show all 625
All 625 locations
Target enrolment
to

Trials with a site in Nanchang

449 of 19282 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
Second Affiliated Hospital of Nanchang University
Not applicable
150
Nanchang
2027-01-01
Not yet open
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-12-14
Recruiting
Hua Huang, MD, PhD
Phase 3
170
Beijing, Chongqing, Zhangzhou, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang
2026-12-01
Not yet open
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
170
Guangzhou, Nanning, Nanchang, Taiyuan, Hangzhou
2026-12-01
Not yet open
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Model of Vaginal Laxity
NCT07933120Vaginal Laxity
Peking University People's Hospital
Observational
500
Beijing, Chengdu, Kunming, Lanzhou, Nanchang, Shenzhen
2026-11-15
Not yet open
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
270
Fuzhou, Harbin, Changsha, Nanchang, Changchun, Shanghai, Taizhou
2026-11-01
Not yet open
Children's Hospital of Fudan University
Phase 2/3
90
Nanchang, Shanghai
2026-11-01
Not yet open
Second Affiliated Hospital of Nanchang University
Phase 1/2
55
Nanchang
2026-11-01
Not yet open
The Preventive Efficacy of ULP for Stress Urinary Incontinence After Pelvic Organ Prolapse Surgery
NCT07923968Stress Urinary Incontinence in Women, Pelvic Organ Prolapse (POP)
Peking University People's Hospital
Not applicable
236
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou
2026-11
Recruiting
Pfizer
Phase 3
432
Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang
2026-10-28
Not yet open
Zhejiang University
Not applicable
166
Kaifeng, Nanchang, Aksu, Hangzhou, Jiaxing, Taizhou
2026-10-15
Not yet open
Validating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials
NCT07868224Knee Osteoarthritis; Insomnia; Cervical Spondylosis; Chronic Low Back Pain; Allergic Rhinitis
Jiangxi University of Traditional Chinese Medicine
Not applicable
30
Nanchang
2026-10-10
Recruiting
Bristol-Myers Squibb
Phase 1/2
84
Beijing, Guangzhou, Zhengzhou, Nanchang, Shanghai
2026-10-06
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Guangzhou, Shijiazhuang, Changchun, Xianyang, Beijing, Fuzhou, Hangzhou, Nanchang
2026-10-02
Not yet open
Xinqiao Hospital of Chongqing
Phase 4
1,168
Haikou, Jingdezhen, Jiujiang, Nanchang
2026-10-01
Not yet open
Shanghai Jeyou Pharmaceutical Co., Ltd.
Phase 3
416
Nanchang
2026-10
Not yet open
Second Affiliated Hospital of Nanchang University
Phase 4
158
Dexing, Nanchang, Wanzai, Yichun, Ganzhou
2026-10
Recruiting
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09-30
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-28
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Beijing, Chengdu, Guangdong Province, Guangzhou, Hangzhou, Nanchang, Wuhan, Zhengzhou
2026-09-24
Recruiting
4D Molecular Therapeutics
Phase 3
514
Beijing, Changchun, Changsha, Haerbin, Hangzhou, Jinan, Lanzhou, Nanchang
2026-09-18
Recruiting
UCB Biopharma SRL
Phase 3
100
Beijing, Chongqing, Nanchang, Suzhou
2026-09-16
Not yet open
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
23
Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan
2026-09-01
Not yet open
Nanjing Miracle Biotechnology Co., Ltd.
Phase 1
30
Nanchang
2026-09
Not yet open
Nanjing Miracle Biotechnology Co., Ltd.
Phase 1
30
Nanchang
2026-09
Not yet open
Jiangxi University of Traditional Chinese Medicine
Not applicable
110
Nanchang
2026-09
Not yet open
Nanjing Miracle Biotechnology Co., Ltd.
Not applicable
24
Nanchang
2026-09
Not yet open
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
48
Guangzhou, Nanchang, Shanghai, Wenzhou, Xi'an
2026-08-31
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Not yet open
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Chongqing, Nanning, Guangzhou, Hohhot, Suzhou, Nanchang, Hangzhou, Taiyuan
2026-08-19
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
42
Beijing, Xinxiang, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-08-15
Recruiting
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Recruiting
Beijing Tiantan Hospital
Observational
3,000
Beijing, Zhengzhou, Wuhan, Suzhou, Nanchang, Shanghai, Chengdu, Hangzhou
2026-08-03
Not yet open
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Recruiting
Shanghai Henlius Biotech
Phase 1
48
Nanchang, Naning, Nanjing, Shanghai, Xiamen
2026-07-30
Recruiting
UCB Biopharma SRL
Phase 2
402
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Shijiazhuang, Yangzhou SHI
2026-07-27
Recruiting
Fujian Medical University Union Hospital
Not applicable
584
Fuzhou, Quanzhou, Nanchang
2026-07-27
Not yet open
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD
NCT07634367COPD (Chronic Obstructive Pulmonary Disease)
DrugOhtuvayre
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
300
Nanchang
2026-07-10
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 1/2
45
Nanchang
2026-07-03
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai, Hangzhou
2026-07-02
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Recruiting
Climb Bio, Inc.
Phase 1/2
30
Mianyang, Baoji, Beijing, Bengbu, Changsha, Hefei, Nanchang, Suzhou
2026-06-30
Recruiting
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, Ürümqi
2026-06-19
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Recruiting
Shanghai Zhongshan Hospital
Not applicable
420
Fuzhou, Xiamen, Guiyang, Zunyi, Wuhan, Suzhou, Nanchang, Shanghai
2026-06-10
Recruiting
iCell Gene Therapeutics
Phase 1
18
Nanchang
2026-06-10
Not yet open
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing
2026-05-31
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang, Changchun, Jinan
2026-05-27
Recruiting
UCB Biopharma SRL
Phase 3
120
Beijing, Chengdu, Chongqing, Nanchang, Suzhou
2026-05-27
Not yet open
Second Affiliated Hospital of Nanchang University
Not applicable
80
Nanchang
2026-05-25
Recruiting
Yanbing Yu
Not applicable
142
Beijing, Nanning, Shijiazhuang, Nanjing, Nantong, Nanchang, Shanghai, Tianjin
2026-05-23
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
NCT07607275Hypertension, Essential (Primary) Hypertension
Beijing Anzhen Hospital
Phase 4
350
Beijing, Chongqing, Dalian, Hohhot, Longyan, Luohe, Nanchang, Nanjing
2026-05-15
Recruiting
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-05-15
Not yet open
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Ipsen
Phase 3
350
Beijing, Guangzhou, Zhengzhou, Nanchang, Changchun, Jinan, Shanghai, Tianjin
2026-05-14
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Beijing, Guangzhou, Meizhou, Nanning, Hong Kong, Wuhan, Nanjing, Nanchang
2026-05-06
Recruiting
Gan Lijun
Not applicable
2,170
Beijing, Haikou, Harbin, Nanchang, Heze, Jinan, Jining, Liaocheng
2026-05-04
Active, closed
Second Affiliated Hospital of Nanchang University
Not applicable
80
Nanchang
2026-05-01
Not yet open
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis
NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
150
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Jinan, Qingdao
2026-04-30
Not yet open
Second Affiliated Hospital of Nanchang University
Phase 2
25
Nanchang
2026-04-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
BioNTech SE
Phase 3
736
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang
2026-04-22
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Active, closed
Thymus Dosimetric and Morphologic Predictors of Radiation-Induced Lymphopenia in Stage III NSCLC
NCT07564089Radiation-induced Lymphopenia, Thymus Dosimetric, Number of Lymphocytes
You Peimeng
Observational
450
Nanchang
2026-04-10
Recruiting
magAssist, Inc.
Not applicable
204
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Suzhou, Xi'an
2026-04-09
Recruiting
Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
NCT07229495Scoliosis; Adolescence, Pain After Surgery, Analgesia, Patient-controlled
DrugsTegileridine·Morphine
Peking Union Medical College Hospital
Phase 4
171
Zhengzhou, Nanchang, Beijing, Shanghai
2026-04-08
Recruiting
Jiangxi Provincial Cancer Hospital
Phase 3
148
Nanchang
2026-04-01
Recruiting
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Not yet open
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
Boehringer Ingelheim
Phase 2
132
Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan
2026-03-23
Recruiting
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Active, closed
University of Malaya
Not applicable
36
Nanchang
2026-03-16
Recruiting
Targeted Temperature Management Via Bladder Monitoring in ICH
NCT07302009Intracerebral Hemorrhage, Targeted Temperature Management
Yanyan Gong
Not applicable
318
Nanchang
2026-03-15
Recruiting
Effect of EIT-guided PEEP in ARDS Patients
NCT06990477ARDS (Acute Respiratory Distress Syndrome)
Southeast University, China
Not applicable
2,400
Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang
2026-03-13
Recruiting
Sanofi
Phase 2/3
526
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Shanghai
2026-03-13
Recruiting
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Not yet open
Shanghai Zhongshan Hospital
Not applicable
24
Nanchang, Shanghai
2026-03-10
Recruiting
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Not yet open
Xinqiao Hospital of Chongqing
Phase 3
786
Chongqing, Haikou, Ganzhou, Ji’an, Nanchang
2026-03-01
Recruiting
Beijing Anzhen Hospital
Not applicable
252
Beijing, Dalian, Jilin City, Nanchang, Shanghai
2026-02-26
Recruiting
Beijing Anzhen Hospital
Not applicable
564
Beijing, Changchun, Dalian, Nanchang, Shanghai
2026-02-25
Recruiting
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
30
Nanchang
2026-02-15
Recruiting
Beijing Geekgene Technology Co., LTD
Early Phase 1
10
Nanchang
2026-02-13
Not yet open
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 1
48
Beijing, Guiyang, Zhengzhou, Nanchang, Hangzhou
2026-02-12
Recruiting
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Harbin, Nanchang, Shanghai, Chengdu
2026-01-29
Recruiting
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Recruiting
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
NCT07362810Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients
DrugG-Csf
Fudan University
Phase 2
224
Fuzhou, Zhengzhou, Nanchang, Shanghai, Hangzhou
2026-01-22
Active, closed
Viatris Pharmaceuticals Co., Ltd.
Phase 2
15
Guangzhou, Shijiazhuang, Luoyang, Zhengzhou, Jiujiang, Nanchang, Beijing
2026-01-14
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Not yet open
Early Surfactant Administration at FiO₂ >0.25 Under NIPPV for RDS in Very Preterm Infants
NCT07100652Respiratory Distress Syndrome (&Amp; [Hyaline Membrane Disease])
Jiulongpo No.1 People's Hospital
Not applicable
384
Nanchang
2026-01-01
Recruiting
Second Affiliated Hospital of Nanchang University
Observational
320
Nanchang
2026-01-01
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Not yet open
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Recruiting
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE
NCT07268560Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
DrugAztreonam-Avibactam
Sir Run Run Shaw Hospital
Observational
100
Nanchang, Hangzhou
2025-12-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2
140
Nanjing, Nanchang, Shanghai, Chengdu
2025-12-19
Active, closed
Jiangxi Provincial Cancer Hospital
Observational
60
Nanchang
2025-12-18
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Not yet open
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Recruiting
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, Ürümqi
2025-12-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Pfizer
Phase 3
450
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
84
Beijing, Fuzhou, Nanchang, Jinan, Shanghai, Hangzhou
2025-12-01
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 2
164
Nanchang
2025-12-01
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Beijing, Guangzhou, Hangzhou, Nanchang
2025-11-26
Recruiting
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
DrugStapokibart
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Sun Yat-sen University
Phase 2
96
Guangzhou, Wuhan, Nanchang, Kunming
2025-11-20
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
BioNTech SE
Phase 3
558
Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
Xinqiao Hospital of Chongqing
Phase 3
820
Wuhan, Xiangtan, Jiujiang, Nanchang
2025-10-21
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Recruiting
Anhui Palo Alto Pharmaceuticals, Inc.
Phase 2
30
Nanchang
2025-10-15
Recruiting
Jiangxi Provincial Cancer Hospital
Phase 2
23
Nanchang
2025-10-10
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining
2025-10-03
Active, closed
Second Affiliated Hospital of Nanchang University
Observational
2,000
Nanchang
2025-10-01
Recruiting
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Recruiting
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
350
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Active, closed
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
Recruiting
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
Jiangxi University of Traditional Chinese Medicine
Phase 1/2
74
Nanchang
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
Nuvation Bio Inc.
Phase 3
180
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang
2025-08-21
Active, closed
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Recruiting
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Recruiting
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
180
Beijing, Jinhua, Nanchang
2025-08-05
Recruiting
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Beijing, Guangzhou, Nanchang, Shanghai, Xi'an
2025-08-04
Recruiting
AbbVie
Phase 2/3
854
Beijing, Fuzhou, Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-08-03
Recruiting
Real World Evidence Study of SYN023 in Children Exposed to Rabies
NCT07327307Rabies Post-exposure Prophylaxis
Synermore Biologics (Suzhou) Co., Ltd.
Observational
232
Beijing, Shenzhen, Changsha, Hengyang, Nanchang
2025-08-02
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
114
Zhengzhou, Nanchang, Shanghai
2025-08-01
Active, closed
3D-Printed Grafts for Knee Cartilage Repair
NCT07312175Osteochondral Lesions of Knee, Osteo Arthritis
Second Affiliated Hospital of Nanchang University
Not applicable
60
Nanchang
2025-08-01
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
70
Nanchang
2025-08-01
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang, Jinan
2025-07-30
Not yet open
Nanchang University Affiliated Rehabilitation Hospital
Observational
400
Nanchang
2025-07-28
Recruiting
Short-term Bactericidal Effect of Contezolid in MAC-PD
NCT07084402Mycobacterium Avium Complex Pulmonary Disease
DrugsAzithromcyin·Ethambutol·Linezolid·Rifampicin
Bin Cao
Phase 4
188
Beijing, Nanchang
2025-07-24
Recruiting
Bin Cao
Phase 4
300
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Bin Cao
Phase 4
188
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Active, closed
Pfizer
Phase 3
151
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Active, closed
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Predictive Performance of a Generative Model for Corneal Tomography After ICL Implantation
NCT07146737ICL, Vault, Deep Learning, AI (Artificial Intelligence)
Second Affiliated Hospital of Nanchang University
Observational
818
Nanchang
2025-07-01
By invitation
Shuzhen Wang
Not applicable
80
Nanchang
2025-07-01
Recruiting
Diagnostic Performance of an AI-based Model for TCM Constitution Classification Using Ophthalmic Imaging
NCT07127939Ophthalmic Imaging, Deep Learning, Artificial Intelligence (AI), Traditional Chinese Medicine Constitution
Second Affiliated Hospital of Nanchang University
Observational
1,024
Nanchang
2025-07-01
By invitation
Nanchang University Affiliated Rehabilitation Hospital
Not applicable
62
Nanchang
2025-06-25
Recruiting
Nanchang University Affiliated Rehabilitation Hospital
Not applicable
40
Nanchang
2025-06-25
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 2
30
Nanchang
2025-06-20
Recruiting
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
24
Nanchang
2025-06-16
Recruiting
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Guangzhou, Wuhan, Nanchang, Taiyuan, Hangzhou
2025-06-12
Recruiting
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2025-06-04
Recruiting
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan
2025-05-26
Recruiting
Pfizer
Phase 2
252
Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang
2025-05-20
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
104
Nanchang
2025-05-15
Active, closed
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin
2025-05-12
Active, closed
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
30
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
50
Nanchang
2025-04-24
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 2/3
30
Nanchang
2025-04-21
Recruiting
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
154
Nanchang
2025-04-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Active, closed
Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection
NCT06934070Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) Prognosis
Qiang Xu
Observational
287
Nanchang
2025-04-03
Recruiting
Peking University Third Hospital
Not applicable
400
Nanchang, Quzhou, Beijing
2025-04-02
Recruiting
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Not yet open
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
NCT06848426Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Jiangxi Provincial People's Hopital
Not applicable
100
Nanchang
2025-03-10
Recruiting
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Not yet open
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation
The First Affiliated Hospital of Dalian Medical University
Not applicable
1,334
Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai
2025-03-03
Recruiting
Shanghai Zhongshan Hospital
Observational
1,450
Guangzhou, Nanchang, Shenyang, Jinan, Shanghai
2025-03-01
Recruiting
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
80
Nanchang
2025-02-26
Recruiting
Anhui Palo Alto Pharmaceuticals, Inc.
Phase 2
60
Nanchang
2025-02-24
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DrugsAWT020·Taxol·Pemetrexed·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Recruiting
Clinical Study of Acupuncture Treatment of Knee Osteoarthritis
NCT06805188Osteoarthritis of the Knees, Osteoarthritis (OA) of the Knee, Osteoarthritis
Wu zenan
Not applicable
350
Nanchang
2025-02-15
Not yet open
The First Affiliated Hospital of Nanchang University
Not applicable
60
Nanchang
2025-02-15
Not yet open
Evaluation of an Artificial Intelligence Model for the Prediction of Human Blastocyst Ploidy Without Invasive Procedures
NCT06762704The Focus is to Validate the Accuracy of a Non-invasive Artificial Intelligence Model for the Prediction of the Human Blastocyst Ploidy, Preimplantation Genetic Testing (PGT)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,408
Hefei, Nanjing, Nanchang, Xi'an, Shanghai
2025-02
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Recruiting
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
NCT07872423Anti IL-6R, Castleman's Disease, Multicentric
Beijing VDJBio Co., LTD.
Phase 3
45
Beijing, Xiamen, Wuhan, Nanjing, Nanchang, Taiyuan, Chengdu, Hangzhou
2025-01-27
Recruiting
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
Pfizer
Phase 3
211
Hefei, Nanchang, Shanghai, Kunming, Beijing
2025-01-22
Recruiting
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Recruiting
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Active, closed
Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma
NCT06762470Histopathological Diagnosis of Nasopharyngeal Carcinoma, Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Jiangxi Provincial Cancer Hospital
Observational
325
Nanchang
2025-01-01
Recruiting
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
NCT06752239Nasopharyngeal Carcinoma, Quality of Life, Thyroid Diseases, Radiotherapy Side Effect
Jiangxi Provincial Cancer Hospital
Phase 3
474
Nanchang
2025-01-01
Active, closed
Second Affiliated Hospital of Nanchang University
Phase 4
80
Nanchang
2025-01-01
Active, closed
Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma
NCT06770699Nasopharyngeal Cancinoma (NPC)
Jiangxi Provincial Cancer Hospital
Observational
260
Nanchang
2025-01-01
Recruiting
Jiangxi Provincial Cancer Hospital
Phase 2
109
Nanchang
2025-01-01
By invitation
Prognostic Value of TIL in Nasopharyngeal Carcinoma
NCT06763640Nasopharyngeal Carcinoma (NPC)
Jiangxi Provincial Cancer Hospital
Observational
216
Nanchang
2025-01-01
Not yet open
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Active, closed
The First Affiliated Hospital of Nanchang University
Not applicable
30
Nanchang
2024-12-28
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsMesutoclax·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xi’an, Chengdu
2024-12-09
Recruiting
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Recruiting
Fei Li
Phase 2
90
Nanchang
2024-12-01
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Active, closed
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Folfox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Not yet open
West China Hospital
Not applicable
150
Nanchang, Chengdu
2024-11-10
By invitation
Second Affiliated Hospital of Nanchang University
Phase 2
37
Nanchang
2024-11-01
Active, closed
Fengli Liu
Observational
900
Nanchang
2024-11-01
Recruiting
Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained
NCT06806085Small-incision Lenticule Extraction (SMILE) Surgery, Corneal Higher-order Wavefront Aberrations, Residual Lenticule
Second Affiliated Hospital of Nanchang University
Observational
33
Nanchang
2024-10-31
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
By invitation
Nanchang University
Not applicable
100
Nanchang
2024-10-01
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Recruiting
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
33
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
2024-09-19
Active, closed
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Recruiting
The First Affiliated Hospital of Nanchang University
Early Phase 1
12
Nanchang
2024-09-05
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Not yet open
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, Ürümqi, Wenzhou
2024-09-01
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Recruiting
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang
2024-08-21
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Active, closed
AbbVie
Phase 3
111
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
20
Nanchang
2024-08-01
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 2
156
Nanchang
2024-07-02
By invitation
Second Affiliated Hospital of Nanchang University
Phase 3
80
Nanchang
2024-07-01
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an
2024-06-11
Recruiting
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
NCT06445803Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Rong Tao
Phase 1
48
Nanchang, Shanghai
2024-05-31
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Active, closed
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Active, closed
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
Simcere Pharmaceutical Co., Ltd
Phase 2
226
Fuyang, Hefei, Huangshan City, Guangzhou, Wuzhou, Shijiazhuang, Zhumadian, Nanchang
2024-04-08
Recruiting
Eye & ENT Hospital of Fudan University
Observational
180
Beijing, Zhengzhou, Changsha, Nanchang, Shanghai, Chengdu
2024-04-06
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
The First Affiliated Hospital of Nanchang University
Phase 2
10
Nanchang
2024-03-11
Recruiting
The First Affiliated Hospital of Nanchang University
Phase 2
10
Nanchang
2024-03-11
Recruiting
Jiangxi Provincial Cancer Hospital
Phase 3
264
Ganzhou, Guangzhou, Nanchang
2024-03-07
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
100
Nanchang
2024-03-01
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Not yet open
The First Affiliated Hospital of Nanchang University
Observational
176
Nanchang
2024-01-21
Recruiting
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
DrugCadonilimab
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Beijing, Changsha, Chengdu, Nanchang, Qingdao, Shanghai, Shenzhen
2024-01-03
Recruiting
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
NCT06182657Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
Jiangxi Provincial Cancer Hospital
Observational
300
Nanchang
2024-01-01
Recruiting
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
By invitation
Second Affiliated Hospital of Nanchang University
Not applicable
256
Nanchang
2024-01-01
Recruiting
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai
2023-12-29
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Recruiting
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xi’an, Tianjin, Hangzhou
2023-12-27
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Recruiting
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Active, closed
argenx
Observational
413
Changsha, Nanchang, Shanghai
2023-11-29
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
By invitation
Second Affiliated Hospital of Nanchang University
Observational
100
Nanchang
2023-11-06
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang
2023-10-12
Recruiting
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Active, closed
Pfizer
Phase 2
507
Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanchang
2023-08-22
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Nanchang, Neijiang
2023-08-18
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Recruiting
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Recruiting
Shandong Cancer Hospital and Institute
Phase 2
31
Nanchang, Jinan
2023-06-01
Recruiting
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
30
Huai'an, Nanchang, Shanghai, Guangzhou
2023-05-15
Recruiting
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
200
Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming
2023-05-11
Recruiting
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Active, closed
Sanofi
Phase 2
118
Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan
2023-04-05
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
20
Nanchang
2023-04-01
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Recruiting
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Recruiting
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
DrugAzacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
198
Nanchang, Suzhou, Zhengzhou
2023-02-14
Recruiting
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Recruiting
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Active, closed
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104Moderate to Severe Ulcerative Colitis
DrugMufemilast
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
92
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2022-11-08
Active, closed
Eli Lilly and Company
Phase 1
17
Wuhu, Changsha, Nanchang, Shanghai
2022-10-09
Recruiting
Second Affiliated Hospital of Nanchang University
Observational
200
Nanchang
2022-10-01
Recruiting
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
GlaxoSmithKline
Phase 3
110
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
Second Affiliated Hospital of Nanchang University
Observational
7,100
Nanchang
2022-09-01
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
112
Nanchang
2022-09-01
Active, closed
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Active, closed
Hrain Biotechnology Co., Ltd.
Early Phase 1
10
Nanchang
2022-08-12
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Recruiting
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
172
Beijing, Nanchang, Chengdu
2022-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-07-20
Active, closed
Qiang Xu
Observational
272
Nanchang
2022-07-01
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
Cloudbreak Therapeutics, LLC
Phase 3
660
Beijing, Chengdu, Haikou, Hengyang, Kunming, Nanchang, Qingdao, Wenzhou
2022-06-30
Active, closed
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Active, closed
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Active, closed
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05252078Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms
DrugsAnlotinib hydrochloride·Benmelstobart
Jiangxi Provincial Cancer Hospital
Phase 2
30
Nanchang
2022-06-02
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Active, closed
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
NCT05593081Diabetes Mellitus, Type 1
Second Xiangya Hospital of Central South University
Observational
240
Quanzhou, Guangzhou, Nanning, Zunyi, Haikou, Changsha, Yancheng, Nanchang
2022-05-20
Active, closed
Eli Lilly and Company
Phase 1
260
Beijing, Nanchang, Shanghai
2022-05-11
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Recruiting
Hoffmann-La Roche
Phase 1
332
Beijing, Guangzhou, Nanchang, Tianjin
2022-03-07
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
DrugsGlecirasib·Cetuximab
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Active, closed
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an
2022-01-04
Recruiting
Xingshun Qi
Observational
3,000
Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan
2022-01-01
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Active, closed
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Recruiting
Chinese University of Hong Kong
Not applicable
236
Beijing, Nanchang, Chengdu
2021-11-27
Recruiting
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Active, closed
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Active, closed
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
90
Nanchang
2021-08
Recruiting
Diagnostic Efficacy of CNN in Predicting Intraoperative Complications and Postoperative Outcomes in SMILE
NCT06204926Deep Convolutional Neural Network, Small-incision Lenticule Extraction (SMILE) Surgery, Intraoperative Complications, Postoperative Outcomes
Second Affiliated Hospital of Nanchang University
Observational
1,250
Nanchang
2021-06-15
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Recruiting
Jidong Jia
Phase 4
100
Beijing, Suzhou, Nanchang, Shanghai, Tianjin
2021-04-20
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Active, closed
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Recruiting
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Not yet open
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
NCT04215510Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
286
Fuzhou, Nanchang, Shanghai
2021-03-01
Active, closed
Celgene
Phase 3
313
Guangzhou, Nanyang, Changsha, Nanjing, Nantong, Nanchang, Qingdao, Taiyuan
2021-02-25
Recruiting
Study on the Diagnostic Efficacy of ICL Selection and Prediction Depth Model Based on Eye Images
NCT06669728Posterior Chamber Phakic Intraocular Lens, Vault, Deep Neural Network, Myopia
Second Affiliated Hospital of Nanchang University
Observational
326
Nanchang
2021-01-02
Active, closed
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Active, closed
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
Sun Yat-sen University
Not applicable
500
Guangzhou, Zhuhai, Nanchang
2020-06-30
Active, closed
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Active, closed
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Recruiting
Amgen
Phase 1
505
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Wenzhou, Nanjing
2020-03-04
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2020-03-01
Recruiting
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Active, closed
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Recruiting
Shanghai Chest Hospital
Phase 3
176
Nanchang, Shanghai, Tianjin
2019-09-01
Active, closed
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Recruiting
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Active, closed
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Recruiting
Second Affiliated Hospital of Nanchang University
Observational
5,000
Nanchang
2018-10-01
Active, closed
AbbVie
Phase 3
1,336
Guangzhou, Shijiazhuang, Wuhan, Changsha, Nanchang, Shanghai, Chengdu, Tianjin
2018-04-09
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Active, closed
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
AbbVie
Phase 3
950
Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai
2017-01-31
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Beijing, Chongqing, Jiamusi, Ji’an, Kaifeng, Liaocheng, Lishui, Nanchang
2016-12
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
DrugPEG-somatropin
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Recruiting
Clinical Risk Score Prediction for Risk of Dementia Among Late-life Population With Depression
NCT07676851Alzheimer Dementia (AD), Dementia, Late Life Depression (LLD), Risk Scores
Second Affiliated Hospital of Nanchang University
Observational
44
Nanchang
2006-06-01
Recruiting
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
NCT07595094Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction, Disease Risk Prediction
Second Affiliated Hospital of Nanchang University
Observational
2,000,000
Nanchang
2006-06-01
Rows per page Showing 1–449 of 449
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-china/city/nanchang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,282 studies in total at the last sync on 14 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 449 of those studies with a site in Nanchang.

How many clinical trials are recruiting in Nanchang?

281 of the 449 studies on this page are recruiting new participants as of the 14 Nov 2026, 03:17 UTC sync. A further 57 have not yet opened recruitment, 102 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanchang), 449 studies
PhaseStudiesRecruitingShare
Phase 31216626.9%
Not applicable814818%
Phase 2815718%
Phase 1533811.8%
Observational472810.5%
Phase 1/235287.8%
Phase 41683.6%
Phase 2/31162.4%
Early Phase 1420.9%

Most active sponsors

Lead sponsors with the most studies (Nanchang)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Nanchang University3724
AbbVie157
The First Affiliated Hospital of Nanchang University1310
Pfizer1210
Sun Yat-sen University129
Jiangxi Provincial Cancer Hospital117
Sanofi114
Hoffmann-La Roche104
Merck Sharp & Dohme LLC108
Novartis Pharmaceuticals104
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.